{
    "url_original": "https://www.wsj.com/articles/covid-19-antibody-drugs-are-challenged-by-omicron-preliminary-testing-indicates-11638270003?mod=business_lead_pos1",
    "url": "covid-19-antibody-drugs-are-challenged-by-omicron-preliminary-testing-indicates-11638270003",
    "title": "Covid-19 Antibody Drugs Are Challenged by Omicron, Preliminary Testing Indicates",
    "sub_head": "Regeneron said its antibody drug cocktail was found to lose effectiveness against the new variant",
    "category_1": "Business",
    "category_2": "Health Care",
    "time": "2021-11-30 06:00:00",
    "body": "Preliminary tests indicate the Covid-19 antibody drug cocktail from Regeneron Pharmaceuticals Inc. loses effectiveness against Omicron, the company said Tuesday, a sign that some products in an important class of therapies might need modifying if the new strain becomes widespread.<br />Separate testing of another authorized Covid-19 antibody drug cocktail, from  Eli Lilly  & Co., indicates it also isn’t as effective against Omicron, outside scientists said. Lilly said it is testing the new variant against its antibody treatment and wouldn’t speculate on what the results will be."
}